ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ABMD
Previous Symbol
CUSIP00365410
Phone978-646-1400
Debt
Debt-to-Equity RatioN/A
Current Ratio6.85
Quick Ratio6.07
Price-To-Earnings
Trailing P/E Ratio133.17
Forward P/E Ratio91.39
P/E Growth2.59
Sales & Book Value
Annual Sales$593.75 million
Price / Sales24.75
Cash Flow$2.8585 per share
Price / Cash Flow114.14
Book Value$15.57 per share
Price / Book20.95
Profitability
EPS (Most Recent Fiscal Year)$2.45
Net Income$112.17 million
Net Margins27.60%
Return on Equity20.09%
Return on Assets17.79%
Miscellaneous
Employees1,143
Outstanding Shares45,040,000
Market Cap$14.30 billion
OptionableOptionable
ABIOMED (NASDAQ:ABMD) Frequently Asked Questions
What is ABIOMED's stock symbol?
ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."
How were ABIOMED's earnings last quarter?
ABIOMED, Inc. (NASDAQ:ABMD) posted its earnings results on Thursday, November, 1st. The medical equipment provider reported $1.09 EPS for the quarter, topping analysts' consensus estimates of $0.73 by $0.36. The medical equipment provider had revenue of $181.78 million for the quarter, compared to the consensus estimate of $175.41 million. ABIOMED had a return on equity of 20.09% and a net margin of 27.60%. The firm's revenue for the quarter was up 36.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.54 earnings per share. View ABIOMED's Earnings History.
When is ABIOMED's next earnings date?
What guidance has ABIOMED issued on next quarter's earnings?
ABIOMED issued an update on its FY 2019 earnings guidance on Thursday, November, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $765-770 million, compared to the consensus revenue estimate of $770.52 million.
What price target have analysts set for ABMD?
7 Wall Street analysts have issued 12-month price objectives for ABIOMED's stock. Their predictions range from $280.00 to $496.00. On average, they anticipate ABIOMED's stock price to reach $396.00 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price. View Analyst Price Targets for ABIOMED.
What is the consensus analysts' recommendation for ABIOMED?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ABIOMED.
Has ABIOMED been receiving favorable news coverage?
Press coverage about ABMD stock has been trending somewhat positive on Tuesday, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ABIOMED earned a news impact score of 1.5 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of ABIOMED's key competitors?
Some companies that are related to ABIOMED include Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Hill-Rom (HRC), Haemonetics (HAE), Insulet (PODD), ICU Medical (ICUI), Penumbra (PEN), Globus Medical (GMED), Integra Lifesciences (IART), Cantel Medical (CMD) and Merit Medical Systems (MMSI).
Who are ABIOMED's key executives?
ABIOMED's management team includes the folowing people:
- Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 51)
- Dr. David M. Weber, Chief Operating Officer (Age 57)
- Mr. Michael G. Howley, VP & GM of Global Sales (Age 54)
- Mr. William J. Bolt, Sr. VP of Global Quality, Regulatory & Clinical Operations (Age 66)
- Mr. Ian McLeod, VP & Corp. Controller
Who are ABIOMED's major shareholders?
ABIOMED's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.32%), Primecap Management Co. CA (7.49%), BlackRock Inc. (6.95%), Renaissance Technologies LLC (3.82%), AQR Capital Management LLC (2.68%) and Baillie Gifford & Co. (1.79%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.
Which institutional investors are selling ABIOMED stock?
ABMD stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., FMR LLC, Scout Investments Inc., Primecap Management Co. CA, Mitsubishi UFJ Trust & Banking Corp, Carillon Tower Advisers Inc., American Century Companies Inc. and Prudential Financial Inc.. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Insider Buying and Selling for ABIOMED.
Which institutional investors are buying ABIOMED stock?
ABMD stock was acquired by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, MERIAN GLOBAL INVESTORS UK Ltd, BlackRock Inc., Vanguard Group Inc., Janus Henderson Group PLC, Marshall Wace North America L.P., Renaissance Technologies LLC and Legal & General Group Plc. View Insider Buying and Selling for ABIOMED.
How do I buy shares of ABIOMED?
Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ABIOMED's stock price today?
One share of ABMD stock can currently be purchased for approximately $326.2650.
How big of a company is ABIOMED?
ABIOMED has a market capitalization of $14.30 billion and generates $593.75 million in revenue each year. The medical equipment provider earns $112.17 million in net income (profit) each year or $2.45 on an earnings per share basis. ABIOMED employs 1,143 workers across the globe.
What is ABIOMED's official website?
How can I contact ABIOMED?
ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]
MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
